Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Vol 11 [6] May2022 : 72-77

Online ISSN 2277-1808
Journal's URL:http://www.bepls.com
CODEN: BEPLAD

REVIEW ARTICLE **OPEN ACCESS**

Challenges and possibilities in Nano-medicine for future clinical applications

Shalini jiwan Chahande[1], Anil Kumar[2], Gunmala Gugalia[3], L. Thimmesha[4], RizwanaBegum[5]
1.Assistant Professor, Department of Biochemistry,SethKesarimalPorwal College of Arts and Science and Commerce,Kamptee 441 001, District - Nagpur, Maharashtra, India.
2. Ex Research Scholar, Department of Botany,DDU Gorakhpur University Gorakhpur-273009.
3. Associate professor, School of Basic & Applied Science, Sangam University, Bhilwara, Rajasthan, 311001.
4. Assistant Professor and HOD,Department of English and Humanities,Government Engineering College Hassan - 573201 Karnataka,Affiliated to Visvesvaraya Technological University Belagavi.
5.Assistant Professor, Department of Mathematics, Anwarul Uloom College,Hyderabad, Telangana 500001.
Correspondence e-mail:sdshalini90@gmail.com

ABSTRACT
Engineered nanostructures have become more widely recognized as potential and potent biomedical instruments or gadgets for scanning, medication administration, as well as therapeutic agents, although only a handful have been evaluated in research trials. The lack of knowledge of nano-particles' biological identification is largely to blame for the large gap between laboratory findings as well as therapeutic use. Whenever nano-materials come into contact with biological matrices, they eventually engage with them and absorb hundreds of macromolecules. The formation of a "biomolecular" on the surface of the nano-particles provides a new biological character to NPs,that controls cell viability, immunological responses, bio-distribution, clearing, including toxicities. That interpretation of the molecule's physiological activities in vivo would be sped up with a thorough understanding of the molecular impact induced by the enzyme in vivo. Almost all research so far has sought to describe the elements of peptides based on NP physicochemical characteristics. Significant developments were discussed to have a better understanding of the influence of nanoparticles' biological impacts on nanoparticle-based technologies. The influence of the synthesis of protein on the bioavailability of nanotechnology has recently gained attention. Ultimately, nanomedicine's problems & potential for future therapeutic interventions were highlighted.
Keywords: *Nanomedicine; Clinical applications, Biomolecular, Physicochemical characteristics*

Received: 18.02.2022 Revised: 11.03.2022 Accepted: 29.03.2022

INTRODUCTION

The majority of engineered nanostructures used in healthcare domains are given to living organisms. The very first point of contact among nanoparticles & bodily samples is determined by the differentiation. Biological molecules in body fluid eventually bond to the surface of nanoparticles (NPs), causing the pure NP to lose its bio identity [1]. Due to the complexity of body samples, researchers have started to adopt the terminology biomolecular in the latest days [2]. Such surfaces "biotransformation" of NPs has an unknown effect on the organizational pharmacokinetic and pharmacodynamic character, as well as their prospective variety of therapeutic capabilities. Only 0.7 percent of the injected nanoparticles dosage gets shipped to primary tumors, according to a review of related evidence over the last 10 years [3]. Another of the cornerstones to closing the gap among their optimistic concept as well as actuality is these unanticipated practices have the potential [4]. The therapeutic implementation of nanotechnology would be accelerated if we have a better knowledge of the proteins and their biochemical reactions. Our article focuses on the current results pertinent to the protein's physiological activities, as well as ways for reducing the protein's detrimental consequences on the pharmacokinetic as well as the toxicity of nanotechnology, in place to enable their conversion to the clinical [5-7].

LITERATURE OF REVIEW

NPs are thought to make contact with cell cultures before the proteins were firmly formed, as well as the physicochemical characteristics features of the pure NPs were thought to characterize their physiological effects. Such an idea, nevertheless, is incorrect [8]. In less than 0.5 minutes, the polypeptide develops on

the surface of NPs in a cultured cells medium in vitro or human plasma in vivo. Whenever NPs were presented to live systems, the initial phase of engagement is this recently found bio-nano interaction among proteins & NPs [9].NPs were identified as undesirable compounds that the mononuclear phagocytic mechanism sequesters, degrades, & eliminates, resulting in the fast clearing, lack of efficiency, as well as significant liver accumulating [10]. The proteins around NPs, rather than just the predicted surfaces of the NPs themself, are what the MPS perceives once they are delivered to the female organism [11]. As a result, a greater knowledge of pharmacological characteristics might aid in the development of more safe and effective nanomedical devices, whether for the administration of drugs, in vivo imaging, diagnoses, as well as other medical applications.

MPS absorption & blood flow periods varied depending on biological materials interaction geometries on photocatalyst surface. Numerous investigations have found that some blood products molecules limit immunological cell mitochondrial absorption, which might be due to enhanced desoponins including albumin &apolipoproteins [12]. Through a reduction in particle–cell membranes adherence, bovine serum albumin deposition on NPs inhibits their intracellular absorption by mononuclear polymorphonuclear leukocytes. When NPs were treated with human serum albumin, considerable suppression of internalization by polymorphonuclear leukocytes is seen [13]. Clustering's presence in the proteins decreases monocytes' inappropriate extracellular absorption. In THP-1 cells, clustering attachment to silver NPs as well as silica NPs inhibits their cellular uptake [14]. When opsonins, including such complementing as well as monoclonal antibodies, were concentrated in the proteins, these drive macrophages absorption as well as, as a result, the MPS removes the NPs quickly from the organism.

EFFECT OF THE PROTEIN

NPs were transported to the MPS' targeted organs and tissues via blood flow, especially buildup in the kidney and liver. As a result, taking approximately to the surface of the particle have an impact on nanoparticle-based biodistribution, which is a significant problem in their therapeutic diagnostics. When gold NPs are conjugated with serum proteins like albumin &ApoE, their preservation in the organs is decreased when compared to citration. Compared to citrated-GNPs as well as ApoE-GNPs, albumin-coated GNPs accumulate more in the lungs as well as brains [15]. Their research interests include are mostly concentrated on the biological impacts of nanotechnology as well as nanosafety in nano biomedical technologies. Furthermore, apolipoprotein A-I opsonization for central nervous system capability is reduced. Curiously, significant levels of apolipoproteins A-1 and A-2 constrained in the protease result including exclusive deposition of HMSNs in the liver and also no concentration in other reticuloendothelial structure organ systems like the peritoneum or the lungs [16]. Vacuous mesoporous silica nanoparticles are packed with fluorine substances to behave as favorable magnetic resonance imaging techniques. There's been no strong agreement on the influence of the proteins on the biodistribution of NPs in general. This crucial problem requires immediate clarification; a greater understanding would allow for more exact instructions for enhancing the sensitivity & performance of NPs for physiological activities.

Effect of the Protein on Nanomedicines

The idea of using NPs to focus diseased tissue for better identification and treatment is a famous & intriguing one. Nevertheless, just 0.7 percent of the nanoparticles dosage supplied is observed to reach a solid tumor. The "holy grail" of nanotechnology is delivering NPs to specific tissues and cells. Understanding how bodily fluids impact personalized medicine targeted is crucial for improving their effectiveness. For focused medication orders, folic acids, transferrin, as well as antibodies to particular receptors were widely utilized (see Figure 1). Dawson & his colleagues initially looked into the protein's effect on targeted powers & voiced concerns about that as well. Researchers showed that when proteins are deposited onto transferrin-functionalized silica NPs, the NPs lose their opportunities to obtain. With transferrin-functionalized tiny polymer-coated FePt NPs, similar behavior has been seen. Moreover, whenever ultrasmall superparamagnetic iron oxide NPs were coupled with specific antibodies, their targeted capacity is maintained in vitro but lost in vivo due to opsonin-based proteins adsorption but not albumin absorption.



Figure 1:Protein effects

This proteins makeup has a significant impact on disease cell internalization. Because complementary opsonization is reduced when additions were reduced in the proteins by serum thermal processing, the internalization of carboxylate modified PS NPs by A549 cells is reduced. The protein's makeup is variable; a magnetism discovery was made to effect saturation magnetization compounds, resulting in higher cellular absorption of SPIOs by HepG2 cells owing to enhanced apolipoprotein binding. In contrast to structure, the number of proteins attached to NPs influences cellular absorption behavior. A polypeptide that alters the cell's entrance process from micropinocytosis to clathrin-dependent endocytosis affects the pathway of apoptosis of exosomes. This molecule's critical function is to act as an inherent trigger for particular NP–cell contacts, laying the groundwork for its logical use of ineffective nanomaterials.

Biosafety of Nanoparticles

Increasing blood biomedical applications of nanoparticles is crucial for their use in biomedicine. The thrombocyte-induced aggregating of bare carboxylated multiwalled carbon nanotubes is reduced by an HSA. Whenever fibrinogen induces CNT-COOH to agglomeration, its impact is likewise reduced. An IgG, on the other hand, fragments thrombocytes, causing thrombocyte aggregate as well as the generation of erythrocyte membranes microscopic particles. Whenever human erythrocytes & thrombocytes were exposed to pure silica NPs, fast human plasma protein synthesis effectively inhibited endothelial dysfunction and low blood platelet stimulation. Clotting factors XII, a protein called in the blood, assists to prevent the inappropriate engagement of the blood clotting cascade caused by silica NP.

A decreased agglomerate rate minimizes nanotechnology cytotoxicity in addition to lowering superoxide radicals. The enzyme may also help to prevent cell damage induced by surfactants. The key contribution to gold nanoparticle-induced cytotoxicity is the synthesizing surfactants, such as cetyltrimethylammonium bromide. Oxidizing agents are a major aspect of silver toxicology in organisms, thus removing Ag+ with the help of soft proteins inhibits AgS2 NPs from causing cytotoxicity effect.

Several studies have found that the proteins reduce NP cytotoxicity by (1) reducing superoxide radicals; (2) decreasing aggregation rates; (3) mitigating surfactant-induced cytotoxicity; and (4) protecting against cytotoxicity caused by biodegradable organic metallic ions (see Figure 2). The faster degradation of organic graphite oxides by proteins, on the other hand, causes an inflammatory reaction in organisms.



Figure 2: The protein mitigates

Monoclonal antibodies as well as complementing are two of the most prominent subunits building blocks of protein. Neutrophil activity is dosage & time-dependent when monoclonal antibodies are attached to PEG-SWCNTs. The complementing program is an effective humoral aspect of immune function, acting as the first line of defense against invaders such as exogenous synthesized NPs. Carbon nanotube attachment is very precise. The amount of engagement of the coagulation cascade via the classical pathway is dramatically altered when MWCNTs are covalently functionalized. The approach is an effective H, which is implicated in the alternate route, meanwhile, has an adverse relationship with MWCNT elemental composition.



Figure 3. Protein nanoparticle interaction

This combination of nano-therapeutics with the immune function poses an exciting obstacle to their in vivo effectiveness. For nanoparticles used in biomedical, hazardous nature as well as the danger of causing allergies & inflammation have long been major concerns. Gold NPs with a polyacrylic acids coating connect to fibrinogen in human plasma & cause it to expand. This expanded fibronectin connects to the integrin target MAC-1, which activates the NF-B signaling pathway, resulting in an inflammatory process.

CONCLUSION

Addressing receptors would still be a viable nanoparticle-based improvement. More importance is attached to the profound consequences of the nutrients on nanocarriers when constructing concise administration of therapeutic intermediaries to infected bacteria: supposed to cover protein molecules should indeed be eliminated to improve persecuting functionality in vivo, as well as MPS approval should indeed be minimized to achieve successful malady site buildup. Due to the variability of the pathogenic surroundings, the "personalized proteins" also provide an opportunity to discover new targeted receptors. Researchers have grounds to suppose that in the upcoming weeks, integrated new devices that rely on protein–nanomaterial relationships would be ready for therapeutic application. At last, the aseptic technique of nanotechnology is critical for medical application. The pharmacological significance of protein–nanoparticle combinations' associations with inherent or adoptive defense is currently being discovered. Strategies for reducing immunological cascade-involved bloodstream protein binding.

ACKNOWLEGEMENT

The authors acknowledge the subjects who were involved in the study.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest for this study

REFERENCES

1. Cai, R., & Chen, C. (2019). The crown and the scepter: roles of the protein corona in nanomedicine. *Advanced Materials*, *31*(45), 1805740.
2. Crommelin, D. J., van Hoogevest, P., & Storm, G. (2020). The role of liposomes in clinical nanomedicine development. What now? Now what?. Journal of Controlled Release, 318, 256-263.
3. Ezhilarasi, T. P., Sudheer Kumar, N., Latchoumi, T. P., &Balayesu, N. (2021). A secure data sharing using IDSS CP-ABE in cloud storage. In Advances in Industrial Automation and Smart Manufacturing (pp. 1073-1085). Springer, Singapore.
4. Latchoumi, T. P., & Parthiban, L. (2021). Quasi oppositional dragonfly algorithm for load balancing in cloud computing environment. Wireless Personal Communications, 1-18.
5. Garikapati, P., Balamurugan, K., Latchoumi, T. P., &Malkapuram, R. (2021). A Cluster-Profile Comparative Study on Machining AlSi7/63% of SiC Hybrid Composite Using Agglomerative Hierarchical Clustering and K-Means. Silicon, 13(4), 961-972.
6. **6.**Pavan, V. M., Balamurugan, K., &Latchoumi, T. P. (2021). PLA-Cu reinforced composite filament: Preparation and flexural property printed at different machining conditions. Advanced composite materials.
7. Colapicchioni, V., Millozzi, F., Parolini, O., & Palacios, D. (2022). Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, e1777.
8. Wang, S., Gao, Y., Jin, Q., & Ji, J. (2020). Emerging antibacterial nanomedicine for enhanced antibiotic therapy. Biomaterials Science, 8(24), 6825-6839.
9. Varahachalam, S. P., Lahooti, B., Chamaneh, M., Bagchi, S., Chhibber, T., Morris, K., ... & Kaushik, A. (2021). Nanomedicine for the SARS-CoV-2: state-of-the-art and prospects. *International journal of nanomedicine*, *16*, 539.
10. Colombo, S., Beck-Broichsitter, M., Bøtker, J. P., Malmsten, M., Rantanen, J., & Bohr, A. (2018). Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. *Advanced Drug Delivery Reviews*, *128*, 115-131.
11. Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019). Cancer nanomedicine for combination cancer immunotherapy. *Nature Reviews Materials*, *4*(6), 398-414.
12. Wu, L. P., Wang, D., & Li, Z. (2020). Grand challenges in nanomedicine. *Materials Science and Engineering: C*, *106*, 110302.
13. Burnouf, T., Agrahari, V., &Agrahari, V. (2019). Extracellular vesicles as nanomedicine: hopes and hurdles in clinical translation. *International journal of nanomedicine*, *14*, 8847.
14. Deepthi, T., & Balamurugan, K. (2019). Effect of Yttrium (20%) doping on mechanical properties of rare earth nano lanthanum phosphate (LaPO4) synthesized by aqueous sol-gel process. *Ceramics International*, *45*(15), 18229-18235.
15. Zheng, C., Li, M., & Ding, J. (2021). Challenges and opportunities of nanomedicines in clinical translation. *BIO Integration*, *2*(2), 57-60.

16. Fu, X., Shi, Y., Qi, T., Qiu, S., Huang, Y., Zhao, X., ... & Lin, G. (2020). Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. *Signal transduction and targeted therapy*, *5*(1), 1-15.
17. Ganipineni, L. P., Danhier, F., &Préat, V. (2018). Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment. *Journal of controlled release*, *281*, 42-57.

CITATION OF THIS ARTICLE

S. J. Chahande, Anil Kumar, Gunmala Gugalia, L. Thimmesha, Rizwana Begum., Challenges and possibilities in Nano-medicine for future clinical applications. . Bull. Env. Pharmacol. Life Sci., Vol 11[6]May 2022: 72-77